Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Index funds win long term largely because of lower costs and broad diversification. This brief introduces the cost advantage and payoff.
27,987 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
NVIDIA and SK Hynix unveil a sweeping memory collaboration that could steady Seoul’s wobbling stock market as AI infr...
Rivian remains valued far below Ford despite big hype around electric-vehicle startups. With Rivian’s deliveries risi...
QuantumScape's solid-state battery efforts could redefine EV charging. This guide digs into what might drive QS stock...
As ELAN reports Q1 2026 earnings, investors want clarity on growth, margins, and guidance. This analysis breaks down ...
Three Dow components lag this year, sharing three pressure points that investors still see as catalysts. Wall Street ...
Investors are placing massive bets on Eli Lilly’s GLP-1 drugs, but the push for a $1 trillion opportunity faces medic...
What could drive Entravision's 2025 earnings, and what should investors watch next? This guide breaks down the driver...
Coty is navigating a shifting beauty market. This guide breaks down coty (coty) 2026 earnings, what the Q3 transcript...
New data shows around 22 million teenagers are earning money online through games, resale, and in-game marketplaces, ...
Cardano’s Hoskinson reignites a long-running clash with Ethereum as investors weigh a fresh UTXO-style proposal. ETH ...
Oil traders confront a rare overbought signal as crude-oil futures haven’t been this overstretched in decades. Market...